7 Papers
2 Citations
Midan Ai is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Immunotherapy & T cell. The author has an hindex of 5, co-authored 7 publications.
Chat about Author
Papers
Targeted hypoxia reduction restores T cell infiltration and sensitizes prostate cancer to immunotherapy
Priyamvada Jayaprakash,Midan Ai,Arthur Liu,Arthur Liu,Pratha Budhani,Todd Bartkowiak,Todd Bartkowiak,Jie Sheng,Casey R. Ager,Casey R. Ager,Courtney Nicholas,Ashvin R. Jaiswal,Yanqiu Sun,Krishna Shah,Sadhana Balasubramanyam,Nan Li,Guocan Wang,Jing Ning,Anna Zal,Tomasz Zal,Tomasz Zal,Michael A. Curran,Michael A. Curran +22 more
TL;DR: Hypoxia disruption and T cell checkpoint blockade may sensitize some of the most therapeutically resistant cancers to immunotherapy.
Unique potential of 4-1BB agonist antibody to promote durable regression of HPV+ tumors when combined with an E6/E7 peptide vaccine
Todd Bartkowiak,Todd Bartkowiak,Shailbala Singh,Guojun Yang,G Galvan,G Galvan,Dhwani Haria,Midan Ai,James P. Allison,James P. Allison,K. Jagannadha Sastry,K. Jagannadha Sastry,Michael A. Curran,Michael A. Curran +13 more
TL;DR: It is demonstrated that coadministration of agonist antibodies targeting the T-cell costimulatory receptor 4-1BB and an intranasal HPV E6/E7 peptide vaccine promoted durable regression in 100% of animals bearing HPV+ TC-1 tumors established in the female reproductive tract.
91
Tumor hypoxia drives immune suppression and immunotherapy resistance
Midan Ai,Pratha Budhani,Jie Sheng,Sadhana Balasubramanyam,Sadhana Balasubramanyam,Todd Bartkowiak,Ashvin R. Jaiswal,Casey R. Ager,Dhwani Haria,Michael A. Curran +9 more
TL;DR: It is found that Evofosfamide-driven disruption of hypoxia zones sensitizes prostate cancer to antibody blockade of CTLA-4 and PD-1 in both transplantable and genetically-engineered murine models of prostate cancer.
Abstract 629: Combination hypoxia-specific chemotherapy and immunotherapy of prostate cancer
Midan Ai,Todd Bartkowiak,Ashvin R. Jaiswal,Krishna Shah,Casey R. Ager,Beatrisa Lerman,Michael A. Curran +6 more
TL;DR: This novel combination of immunotherapy and hypoxia-specific chemotherapy has the potential to offer profound anti-tumor responses to a much greater percentage of patients than either chemotherapy or immunotherapy alone with the same or fewer side effects.
1
Abstract IA11: Reversal of immunotherapy resistance through hypoxia reduction
TL;DR: Jayaprakash et al. as discussed by the authors showed that the hypoxia-activated prodrug TH-302 (evofosfamide) can reduce the volume of some solid tumors by triggering a tissue-remodeling process that culminates in revascularization with organized, functional vessels.
1